Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30617138.
- Also identified by DOI 10.1158/1078-0432.CCR-18-3778 and PMC identifier 6445700.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Next-generation sequencing has provided information on actionable targets and biomarkers of response in oncology. In hepatocellular carcinoma (HCC), Wnt/CTNNB1 mutations characterize the immune-excluded class (cold tumors) and might represent the biomarkers predicting resistance to immune checkpoint inhibitors. Large-scale validation of these data is needed to customize immunotherapy in advanced HCC.<i>See related article by Harding et al., p. 2116</i>.
Medical subject headings
- Carcinoma, Hepatocellular
- Liver Neoplasms